Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
PainReform Ltd. PRFX
$0.61
-$0 (-0.20%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
7473164.00000000
-
week52high
1.29
-
week52low
0.34
-
Revenue
86000
-
P/E TTM
-839
-
Beta
-0.20275000
-
EPS
-0.96000000
-
Last Dividend
0.00000000
-
Next Earnings Date
16 мар 2023 г. в 12:00
Описание компании
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
01 сент 2022 г. в 08:00
TEL AVIV, Israel, Sept. 01, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022. The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.